2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
Heart failure: an update from the last years and a look at the near future
M Riccardi, AM Sammartino, M Piepoli… - ESC heart …, 2022 - Wiley Online Library
In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …
[HTML][HTML] Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …
Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial
Importance Heart failure with reduced ejection fraction is a progressive clinical syndrome,
and many patients' condition worsen over time despite treatment. Patients with more severe …
and many patients' condition worsen over time despite treatment. Patients with more severe …
Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial
Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …
Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF
Abstract Background In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac
outcomes Through Improving Contractility in Heart Failure)(n= 8,256), the cardiac myosin …
outcomes Through Improving Contractility in Heart Failure)(n= 8,256), the cardiac myosin …
Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-reduced trial
Background The relationship between the benefits of empagliflozin in heart failure with
reduced ejection fraction (HFrEF) and N-terminal pro–B-type natriuretic peptide (NT …
reduced ejection fraction (HFrEF) and N-terminal pro–B-type natriuretic peptide (NT …
A year in heart failure: an update of recent findings
Major changes have occurred in these last years in heart failure (HF) management.
Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis …
Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis …
Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the dapagliflozin and prevention of …
Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …